p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1

Proteasomal degradation of p53 is mediated by two alternative pathways that are either dependent or independent of both Mdm2 and ubiquitin. The ubiquitin-independent pathway is regulated by NAD(P)H: quinone oxidoreductase 1 (NQO1) that stabilizes p53. The NQO1 inhibitor dicoumarol induces ubiquitin-independent p53 degradation. We now show that, like dicoumarol, several other coumarin and flavone inhibitors of NQO1 activity, which compete with NAD(P)H for binding to NQO1, induced ubiquitin-independent p53 degradation and inhibited wild-type p53-mediated apoptosis. Although wild-type p53 and several p53 mutants were sensitive to dicoumarol-induced degradation, the most frequent “hot-spot” p53 mutants in human cancer, R175H, R248H, and R273H, were resistant to dicoumarol-induced degradation, but remained sensitive to Mdm2-ubiquitin-mediated degradation. The two alternative pathways for p53 degradation thus have different p53 structural requirements. Further mutational analysis showed that arginines at positions 175 and 248 were essential for dicoumarol-induced p53 degradation. NQO1 bound to wild-type p53 and dicoumarol, which induced a conformational change in NQO1, inhibited this binding. Compared with wild-type p53, the hot-spot p53 mutants showed increased binding to NQO1, which can explain their resistance to dicoumarol-induced degradation. NQO1 thus has an important role in stabilizing hot-spot p53 mutant proteins in human cancer.

[1]  A. Jaiswal,et al.  NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues , 1993, Cancer and Metastasis Reviews.

[2]  R. Roeder,et al.  S Phase Activation of the Histone H2B Promoter by OCA-S, a Coactivator Complex that Contains GAPDH as a Key Component , 2003, Cell.

[3]  R. Goodman,et al.  Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  David Siegel,et al.  Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* , 2003, The Journal of Biological Chemistry.

[5]  J. Mcclellan.  Ancient Roots Forced into Modern Pots , 2002, Science.

[6]  J. Lotem,et al.  Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Lotem,et al.  Cytokine control of developmental programs in normal hematopoiesis and leukemia , 2002, Oncogene.

[8]  J. Lotem,et al.  NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Qinghong Zhang,et al.  Regulation of Corepressor Function by Nuclear NADH , 2002, Science.

[10]  L. Amzel,et al.  Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. , 2001, Biochemistry.

[11]  Jiandong Chen,et al.  Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization* , 2001, The Journal of Biological Chemistry.

[12]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[13]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[14]  Jiandong Chen,et al.  Stabilization of the MDM2 Oncoprotein by Mutant p53* , 2001, The Journal of Biological Chemistry.

[15]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[16]  S. Chen,et al.  Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). , 2000, Free radical biology & medicine.

[17]  T. Soussi.  The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[18]  C. S. Yang,et al.  Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. , 1999, Molecular pharmacology.

[19]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[20]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[21]  D. Lane,et al.  p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding , 1997, Oncogene.

[22]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[23]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[24]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[25]  C. Prives.  How loops, β sheets, and α helices help us to understand p53 , 1994, Cell.

[26]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[27]  J. Horwitz,et al.  Chaperone-like activity of alpha-crystallin. The effect of NADPH on its interaction with zeta-crystallin. , 1994, The Journal of biological chemistry.

[28]  D. Chowdary,et al.  Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway , 1994, Molecular and cellular biology.

[29]  R. Metcalf,et al.  p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. , 1993, Carcinogenesis.

[30]  S. Chen,et al.  Inhibition of NAD(P)H:quinone acceptor oxidoreductase by flavones: a structure-activity study. , 1993, Archives of biochemistry and biophysics.

[31]  A. Malkinson,et al.  Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł. , 1992, Cancer research.

[32]  K. Danenberg,et al.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.

[33]  P. Talalay,et al.  Inhibition of NAD(P)H:(quinone-acceptor) oxidoreductase by cibacron blue and related anthraquinone dyes: a structure-activity study. , 1992, Biochemistry.

[34]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[35]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[36]  K. Hayashi,et al.  Properties and reaction mechanism of DT diaphorase from rat liver. , 1974, The Journal of biological chemistry.

[37]  W. Wosilait,et al.  Comparative study of the binding of coumarin anticoagulants and serum albumins. , 1971, Biochemical pharmacology.